Transplanting insulin-producing stem cells for treating Type 1 Diabetes
Official title: Autologous Insulin Producing Mesenchymal Stem Cell Transplantation in Youth With Type 1 Diabetes
Run by Ain Shams University · NCT06951074 · Data updated 2026-11-12
This study is testing whether transplanting insulin-producing stem cells from fat can help people with Type 1 Diabetes better control their blood sugar levels.
Quick facts
| Phase | Phase2; Phase3 |
|---|---|
| Study type | Interventional |
| Ages | 15 Years to 18 Years |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | Ain Shams University Academic / other |
| Locations | 1 site (Cairo) |
| Status | Recruiting |
| Started | April 1, 2025 |
| Main results expected | May 1, 2026 |
| Study ends | September 1, 2026 |
| Registry record updated | April 30, 2025 |
| Trial ID | NCT06951074 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are individuals diagnosed with Type 1 Diabetes who do not have other autoimmune diseases or chronic conditions.
✕Probably not a fit
Patients with other autoimmune diseases or those experiencing micro or macro vascular complications may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial investigates the use of autologous insulin-producing mesenchymal stem cells derived from adipose tissue to treat patients with Type 1 Diabetes. The study aims to differentiate these stem cells into insulin-producing cells and assess their ability to regulate blood sugar levels post-transplant. By utilizing a multistep differentiation technique, the researchers hope to restore pancreatic function and improve glycemic control in participants. The trial will evaluate both in vitro and in vivo insulin production following the infusion of these stem cells.
Why it matters
Potential benefit: If successful, this approach could significantly improve glycemic control and reduce the dependency on insulin therapy for patients with Type 1 Diabetes.
How similar studies have gone: Other studies have shown promise in using stem cell therapies for Type 1 Diabetes, but this specific approach using adipose-derived mesenchymal stem cells is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Type 1 diabetes Exclusion Criteria: * patients with other autoimmune diseases * patients with micro or macro vascular complications * patients with other chronic diseases
Where it's running
-
Children Hospital Eldemerdash
Cairo, Egypt Recruiting
Study contacts
- Principal investigator: Rasha S Elmetwally, A. Prof — Assistant professor of Pediatrics, Faculty of Medicine, Ain Shams University
- Study coordinator: Rasha S Elmetwally, MD
- Email: dr.rashaeladawy@med.asu.edu.eg
- Phone: 20201092143033
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Semaglutide on body composition in adults with type 1 diabetes and overweight/obesity
This study tests whether weekly semaglutide changes body composition in adults with type 1 diabetes who are overweight or obese, compared with a placebo over 24 weeks.
-
Next Generation Extended Wear Sensors in Type 1 and Type 2 Diabetes
This study tests a new extended wear sensor and algorithm in people with type 1 or type 2 diabetes to see how well it works across adults and children.
-
CGM-guided carb awareness education for adults with Type 1 diabetes
This study tests whether teaching mealtime insulin dosing using CGM data helps adults with Type 1 diabetes who don’t usually count carbs.
-
Safety and effectiveness of GLP-1 receptor agonists and SGLT inhibitors added to insulin in adults with type 1 diabetes
This registry will see if adding GLP-1RA or SGLTi therapies to insulin helps adults with type 1 diabetes over one year.
-
Think-Find-Solve activities for insulin self-management in children with type 1 diabetes
A behavior-change activity book is tested with children aged 8–12 with type 1 diabetes and their parents to see if it improves daily insulin self-management.
-
Near-sensor insulin delivery with CGM in people with type 1 diabetes
A small early-feasibility study tests a dual-port insulin patch pump that includes a CGM sensor to see if delivering insulin near the sensor affects glucose readings and whether an automated control algorithm can manage glucose.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.